NYSE : BDX

Becton, Dickinson and Company

$159.93 USD

$5.05 (3.26%)

Volume
112.3K
Average Volume
2.93M
Market Capitalization
$57.94B
P/E Ratio
40.32
Dividend Yield
2.35%
Price Target
$175.00
Year High
$187.35
Year Low
$127.59
Day High
Day Low
Payout Ratio
$1.04
Current Ratio
$0.94
Source Headline
BD to Announce Financial Results for its Third Quarter of Fiscal 2026

FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.

prnewswire.com - 2026-07-09 16:15:00

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-08 13:10:22

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.

fool.com - 2026-07-07 17:30:00

5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years

Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.

fool.com - 2026-07-07 14:00:00

Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There

Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX maintains a BBB rating, conservative leverage, a 2.78% dividend with 44+ years of increases, and is executing $2B in buybacks while retiring $2.1B in debt.

seekingalpha.com - 2026-07-01 11:32:19

BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System

Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company.

prnewswire.com - 2026-06-23 06:50:00

5 Dividend Stocks to Buy and Hold Forever

Get rich slowly. How? Hold these stocks and reinvest the dividends they pay.

fool.com - 2026-06-22 06:15:00

3 Excellent Dividend Stocks to Buy on the Dip

Despite facing some headwinds, these three companies still have strong long-term prospects. All three have raised their payouts for more than 50 consecutive years.

fool.com - 2026-06-22 01:45:00

Rep Thomas Kean just filed 4 new congressional stock trades

Representative Thomas H. Kean Jr, a Republican from New Jersey who sits on the House Energy and Commerce Committee, has disclosed four new congressional stock trades.

finbold.com - 2026-06-19 13:52:52

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

Here's Why You Should Retain BDX Stock in Your Portfolio Now

Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.

zacks.com - 2026-06-16 10:56:16

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

seekingalpha.com - 2026-06-05 18:19:56

Jim Cramer: Buy Becton Dickinson, This Tech Stock Has Too High Valuation

On CNBC's “Mad Money Lightning Round,” Jim Cramer said about JFrog Ltd (NASDAQ:FROG) that the multiple "is too high," although software development "is a good business." The stock has risen more than 40% year-to-date, against the backdrop of exploding demand for AI coding agents and LLMs (large language models).

benzinga.com - 2026-06-04 05:25:02

Best 3 Blue Chip Stocks to Buy After a Market Pullback -- Including Microsoft (MSFT) Stock

One of these stocks sports a dividend yield topping 5%.

fool.com - 2026-05-29 00:00:00

BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care

BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.

zacks.com - 2026-05-22 11:16:47

BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System

New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures. FRANKLIN LAKES, N.J.

prnewswire.com - 2026-05-21 06:50:00

Peter Menziuso Named EVP and President, BD Interventional

FRANKLIN LAKES, N.J., May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1.

prnewswire.com - 2026-05-18 06:50:00

AI, Robotics Key to Transforming Health Care: BD CEO

Tom Polen, CEO of medical technology company BD, says that in the next decade AI and robotics will transform health care in ways that will make today's system seem archaic. Polen sits down with Bloomberg's Caroline Hyde on the sidelines of the Consello Spark Summit.

youtube.com - 2026-05-15 10:36:15

Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 17:20:46

Is Becton Dickinson & Co (BDX) a Bargain After 4.2% Drop? GF Value Says Undervalued

On May 11, 2026, Becton Dickinson and Co (BDX) shares fell 4.2% today, closing at $143.15. This decline continues a downward trend over the past month, where the

gurufocus.com - 2026-05-11 20:02:00

Becton, Dickinson and Company Q2 Earnings Call Highlights

Becton, Dickinson and Company NYSE: BDX reported fiscal second-quarter revenue and adjusted earnings ahead of its internal expectations, while management raised its full-year adjusted earnings outlook and said growth was broad-based across most of the portfolio.

marketbeat.com - 2026-05-09 10:09:34

Is the Options Market Predicting a Spike in Becton Dickinson Stock?

Investors need to pay close attention to BDX stock based on the movements in the options market lately.

zacks.com - 2026-05-07 16:05:45

BD Stock Up in Pre-Market Post Q2 Earnings & Revenue Beat, Margins Up

BDX beats second-quarter fiscal 2026 earnings and revenue estimates, driven by broad segment strength and improved profitability.

zacks.com - 2026-05-07 11:35:20

Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript

Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 11:21:19

Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q2 Earnings

While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com - 2026-05-07 10:31:36

Becton Dickinson (BDX) Q2 Earnings and Revenues Surpass Estimates

Becton Dickinson (BDX) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $3.35 per share a year ago.

zacks.com - 2026-05-07 08:46:26

Becton Dickinson raises annual profit forecast on strength in drug delivery devices

Becton Dickinson raised its annual profit forecast on Thursday, riding strong demand for its drug-delivery devices and surgical equipment, and appointed Vitor ​Roque as its chief financial officer.

reuters.com - 2026-05-07 07:57:34

BD Appoints Vitor Roque Chief Financial Officer

FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7.

prnewswire.com - 2026-05-07 06:31:00

BD Reports Second Quarter Fiscal 2026 Financial Results

Revenue of $4.7 billion increased 5.2% as reported, 2.6% FXN GAAP and adjusted diluted EPS from continuing operations of $(0.13) and $2.90, respectively Executed a $2.0 billion accelerated share repurchase (ASR) program and retired $2.1 billion of debt in the quarter Company reaffirms revenue growth guidance, raises full-year adjusted diluted EPS guidance1 FRANKLIN LAKES, N.J., May 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 second quarter, which ended March 31, 2026.

prnewswire.com - 2026-05-07 06:30:00

Seeking Clues to Becton Dickinson (BDX) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Becton Dickinson (BDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.

zacks.com - 2026-05-05 10:16:06

BD and Wellstar Advance Patient Care and Safety with Medication Management Powered by AI

By integrating the BD Pyxis™ Pro and BD Alaris™ platforms, Wellstar Health System is giving clinicians clearer insight, greater accuracy and simple automation, so they can focus on delivering safer, more consistent care to every patient FRANKLIN LAKES, N.J. and MARIETTA, Ga.

prnewswire.com - 2026-05-05 06:50:00

Madison Small Cap Fund Q1 2026 Portfolio Activity

ICU Medical's new high-volume pump has more connected features, which we believe will drive retention rates and incremental revenue. SiteOne Landscape Supply controls 18% of this $26 billion industry and has been growing revenue at a low double-digit compound annual growth rate over the past several years. Madison Small Cap Fund liquidated its position in Globus Medical after a multi-year period because the company's success drove its market cap to $12B.

seekingalpha.com - 2026-05-04 22:35:00

Can Sustained Product Momentum Drive BDX Stock Before Q2 Earnings?

BD rides on Medical and Interventional product momentum, but China dynamics and research funding could weigh on second-quarter fiscal 2026 results.

zacks.com - 2026-05-04 14:50:53

Earnings Preview: Becton Dickinson (BDX) Q2 Earnings Expected to Decline

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-30 11:06:57

BD Achieves Excellence in Employee Well‑Being, Earning Top Industry Recognition

Business Group on Health, Cigna Healthcare, and the American Heart Association highlight BD's comprehensive and innovative approach to advancing employee health and well being FRANKLIN LAKES, N.J., April 30, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been recognized by Business Group on Health for its commitment to advancing employee well-being through comprehensive and innovative benefits and initiatives.

prnewswire.com - 2026-04-30 06:50:00

BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology

With the launch of CentroVena One™, BD brings a first ‑ of ‑ its ‑ kind insertion system to market that simplifies central line placement for clinicians and enhances care in acute settings FRANKLIN LAKES, N.J., April 29, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial launch of the BD® CentroVena One™ Insertion System, the first all-in-one central venous catheter (CVC) insertion device on the market.

prnewswire.com - 2026-04-29 06:50:00

BD Board Declares Dividend

FRANKLIN LAKES, N.J., April 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on June 30, 2026, to holders of record on June 9, 2026.

prnewswire.com - 2026-04-28 16:15:00

BD to Present at Bank of America Securities Health Care Conference

FRANKLIN LAKES, N.J., April 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference on Tuesday, May 12, 2026 at 11:40 am Eastern Time.

prnewswire.com - 2026-04-27 16:15:00

Best Dividend Kings: April 2026

Dividend Kings are outperforming SPY year-to-date, with 36 of 58 beating the index with an average gain of 7.03% versus SPY's 4.18%. Twenty-seven Dividend Kings are both potentially undervalued and offer a long-term annualized expected return of at least 10%. Recent dividend increases among Kings have been modest, with the average 2026 dividend growth rate rising to 3.11%.

seekingalpha.com - 2026-04-24 20:26:15

Here Are 3 Medical Supply Stocks to Consider Amid Rising Prospects

Here, we highlight three dental supplies stocks, CAH, COO and BDX, which are well positioned to generate wealth for investors amid macro uncertainty.

zacks.com - 2026-04-20 15:46:11

Becton, Dickinson: Value Or Overvalued Even Now?

Becton, Dickinson is rated a 'BUY' under $160/share, driven by attractive fundamentals and a conservative valuation approach. Despite the recent spin-off of its high-margin bioscience segment, BDX retains core medtech operations with solid profitability and robust cash flow generation. I see BDX's current 13x P/E as undervalued, with a fair value target of $215/share by 2028E and an annualized return above 15% at current prices.

seekingalpha.com - 2026-04-20 06:35:45

The Healthcare Stock Built for Investors Who Prioritize Capital Preservation

Becton, Dickinson has been increasing its dividend for more than 50 consecutive years. While diversified, much of its revenue comes from recurring sales of medical supplies.

fool.com - 2026-04-17 16:35:00

3 Magnificent Dividend Stocks the Sell-Off Has Put on Sale. Buy Them Now and Hold Forever.

Becton, Dickinson has become oversold following a spinoff, but analysts call for a growth rebound starting next year. PepsiCo is another oversold Dividend King, trading at multiyear lows, with a historically high forward dividend yield.

fool.com - 2026-04-17 05:35:00

3 Healthcare Stocks That Have Held Up in Every Market Downturn

This trio has typically outpaced the S&P 500 in economic downturns. The three are healthcare leaders with plenty of size and diversity.

fool.com - 2026-04-16 13:47:00

Here's Why You Should Retain BDX Stock in Your Portfolio Now

BD benefits from innovation, strategic deals and strong Q1 results, but reimbursement risks and estimate cuts may temper near-term upside.

zacks.com - 2026-04-16 12:51:06

BD Earns Industry Top Honors for Transparency, Resiliency and Partnership

FRANKLIN LAKES, N.J., April 16, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has been recognized by the Healthcare Industry Resilience Collaborative (HIRC) as the only supplier to receive HIRC's inaugural Member Choice Awards across three categories, Transparency, Resiliency and Partnership.

prnewswire.com - 2026-04-16 06:50:00

Get BDX Insider Trade Alerts

BDX Price Target Summary

Last Month

$180.00

1 analysts

Last Quarter

$181.00

3 analysts

Last Year

$174.11

12 analysts

All Time

$202.70

33 analysts

BDX Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-07-06 Evercore ISI Group Maintain Outperform Outperform
2026-05-11 Barclays Maintain Overweight Overweight
2026-05-08 Wells Fargo Maintain Equal Weight Equal Weight
2026-05-04 TD Cowen Maintain Hold Hold
2026-04-17 Piper Sandler Maintain Neutral Neutral
2026-03-26 Piper Sandler Maintain Neutral Neutral
2026-03-23 Argus Research Maintain Buy Buy
2026-02-11 Citigroup Maintain Buy Buy
2026-02-10 Jefferies Maintain Buy Buy
2026-02-10 RBC Capital Maintain Sector Perform Sector Perform
2026-02-10 Wells Fargo Maintain Equal Weight Equal Weight
2026-02-10 Piper Sandler Maintain Neutral Neutral
2026-02-10 JP Morgan Maintain Neutral Neutral
2026-02-10 Citigroup Maintain Buy Buy
2026-01-28 Piper Sandler Maintain Neutral Neutral
2026-01-07 Stifel Maintain Buy Buy
2026-01-05 B of A Securities Maintain Neutral Neutral
2025-12-17 RBC Capital Maintain Sector Perform Sector Perform
2025-12-02 Morgan Stanley Maintain Overweight Overweight
2025-11-07 Piper Sandler Maintain Neutral Neutral
2025-11-07 RBC Capital Maintain Sector Perform Sector Perform
2025-10-16 RBC Capital Maintain Sector Perform Sector Perform
2025-08-11 Morgan Stanley Maintain Overweight Overweight
2025-08-08 Piper Sandler Maintain Neutral Neutral
2025-08-08 Wells Fargo Maintain Equal Weight Equal Weight
2025-06-03 Barclays Maintain Overweight Overweight
2025-05-22 Citigroup Downgrade Buy Neutral
2025-05-06 Morgan Stanley Maintain Overweight Overweight
2025-05-02 Piper Sandler Downgrade Overweight Neutral
2025-05-02 Stifel Maintain Buy Buy
2025-05-01 Citigroup Maintain Buy Buy
2025-05-01 William Blair Downgrade Outperform Market Perform
2025-04-23 Piper Sandler Maintain Overweight Overweight
2025-04-07 Barclays Maintain Overweight Overweight
2025-02-14 Barclays Maintain Overweight Overweight
2025-01-28 Piper Sandler Maintain Overweight Overweight
2025-01-22 Barclays Maintain Overweight Overweight
2024-10-01 Evercore ISI Group Maintain Outperform Outperform
2024-10-01 Citigroup Upgrade Neutral Buy
2024-08-02 Raymond James Maintain Outperform Outperform
2024-07-26 Stifel Maintain Buy Buy
2024-07-10 Citigroup Maintain Neutral Neutral
2024-07-02 Evercore ISI Group Maintain Outperform Outperform
2024-05-06 Barclays Maintain Overweight Overweight
2024-02-05 Barclays Maintain Overweight Overweight
2024-01-03 Raymond James Maintain Outperform Outperform
2023-12-04 Morgan Stanley Maintain Overweight Overweight
2023-11-10 Raymond James Maintain Outperform Outperform
2023-11-10 Piper Sandler Maintain Overweight Overweight
2023-08-21 Citigroup Maintain Neutral Neutral
2023-08-07 Barclays Maintain Overweight Overweight
2023-08-04 Raymond James Maintain Outperform Outperform
2023-08-04 Morgan Stanley Maintain Overweight Overweight
2023-07-24 Piper Sandler Maintain Overweight Overweight
2023-07-24 Raymond James Upgrade Market Perform Outperform
2023-05-08 Barclays Maintain Overweight Overweight
2023-05-08 Citigroup Maintain Neutral Neutral
2023-05-05 Piper Sandler Upgrade Neutral Overweight
2023-04-12 Keybanc Upgrade Sector Weight Overweight
2023-04-04 Evercore ISI Group Maintain Outperform Outperform
2023-02-03 Morgan Stanley Maintain Overweight Overweight
2023-02-03 Piper Sandler Maintain Neutral Neutral
2023-01-06 Morgan Stanley Maintain Overweight Overweight
2023-01-03 B of A Securities Upgrade Neutral Buy
2022-12-12 Citigroup Upgrade Sell Neutral
2022-11-23 Goldman Sachs Maintain Buy Buy
2022-11-11 Piper Sandler Maintain Neutral Neutral
2022-10-11 Morgan Stanley Maintain Overweight Overweight
2022-08-16 Goldman Sachs Maintain Buy Buy
2022-07-18 Stifel Maintain Buy Buy
2022-07-15 Morgan Stanley Maintain Overweight Overweight
2022-07-11 Citigroup Downgrade Neutral Sell
2022-06-24 Wells Fargo Upgrade Equal Weight Overweight
2022-05-06 Piper Sandler Maintain Neutral Neutral
2022-05-06 Morgan Stanley Maintain Overweight Overweight
2022-04-11 Morgan Stanley Maintain Overweight Overweight
2022-04-01 Wells Fargo Maintain Equal Weight Equal Weight
2022-03-28 Morgan Stanley Maintain Overweight Overweight
2022-02-04 SVB Leerink Maintain Market Perform Market Perform
2022-02-04 Morgan Stanley Maintain Overweight Overweight
2022-01-07 Morgan Stanley Maintain Overweight Overweight
2021-12-08 Piper Sandler Downgrade Overweight Neutral
2021-08-06 JP Morgan Downgrade Overweight Neutral
2021-08-06 SVB Leerink Maintain Market Perform Market Perform
2021-05-25 Barclays Maintain Equal Weight Equal Weight
2021-05-07 SVB Leerink Maintain Market Perform Market Perform
2021-02-05 Citigroup Maintain Neutral Neutral
2021-01-29 Raymond James Maintain Outperform Outperform
2020-12-15 Wells Fargo Downgrade Overweight Equal Weight
2020-12-15 Morgan Stanley Upgrade Equal Weight Overweight
2020-11-06 Morgan Stanley Maintain Equal Weight Equal Weight
2020-10-12 Raymond James Maintain Outperform Outperform
2020-08-27 Morgan Stanley Maintain Equal Weight Equal Weight
2020-08-10 UBS Maintain Neutral Neutral
2020-08-10 Morgan Stanley Maintain Equal Weight Equal Weight
2020-08-07 Raymond James Maintain Outperform Outperform
2020-07-15 SVB Leerink Maintain Market Perform Market Perform
2020-07-09 Barclays Upgrade Equal Weight Overweight
2020-06-25 Morgan Stanley Maintain Equal Weight Equal Weight
2020-06-25 Raymond James Maintain Outperform Outperform
2020-06-01 Goldman Sachs Maintain Buy Buy
2020-05-14 Piper Sandler Maintain Overweight Overweight
2020-05-08 SVB Leerink Maintain Market Perform Perform
2020-05-08 CFRA Maintain Hold Hold
2020-05-08 Raymond James Maintain Outperform Outperform
2020-05-08 Stifel Maintain Buy Buy
2020-05-08 UBS Maintain Neutral Neutral
2020-05-08 Citigroup Maintain Neutral Neutral
2020-04-08 Wells Fargo Maintain Overweight Overweight
2020-04-08 SVB Leerink Maintain Market Perform Market Perform
2020-04-01 Stifel Maintain Buy Buy
2020-03-27 Morgan Stanley Maintain Equal Weight Equal Weight
2020-03-27 Citigroup Maintain Neutral Neutral
2020-03-05 Citigroup Maintain Neutral Neutral
2020-02-07 Cowen & Co. Downgrade Outperform Market Perform
2020-02-07 Raymond James Downgrade Strong Buy Outperform
2020-02-07 Keybanc Downgrade Overweight Sector Weight
2020-02-07 Wells Fargo Maintain Overweight Overweight
2020-02-07 Morgan Stanley Maintain Equal Weight Equal Weight
2020-02-07 KeyBanc Downgrade Overweight Sector Weight
2020-02-06 CFRA Downgrade Buy Hold
2020-01-22 KeyBanc Maintain Overweight Overweight
2020-01-22 Keybanc Maintain Overweight Overweight
2020-01-08 Barclays Downgrade Overweight Equal Weight
2019-12-20 JP Morgan Maintain Overweight Overweight
2019-12-17 Morgan Stanley Maintain Equal Weight Equal Weight
2019-12-16 Stifel Maintain Buy Buy
2019-12-16 Stifel Nicolaus Maintain Buy Buy
2019-11-13 Keybanc Maintain Overweight Overweight
2019-11-13 KeyBanc Maintain Overweight Overweight
2019-11-06 Wells Fargo Maintain Outperform Outperform
2019-09-06 Wells Fargo Maintain Outperform Outperform
2019-07-16 Morgan Stanley Maintain Equal Weight Equal Weight
2019-06-28 Raymond James Maintain Strong Buy Strong Buy
2019-05-13 Barclays Upgrade Equal Weight Overweight
2019-05-10 Keybanc Maintain Overweight Overweight
2019-05-10 KeyBanc Maintain Overweight Overweight
2019-05-10 Morgan Stanley Maintain Equal Weight Equal Weight
2019-05-10 BMO Capital Maintain Market Perform Market Perform
2019-05-10 UBS Maintain Neutral Neutral
2019-04-15 Barclays Maintain Equal Weight Equal Weight
2019-03-19 Raymond James Maintain Strong Buy Strong Buy
2019-01-02 Citigroup Maintain Buy Buy
2019-01-02 Morgan Stanley Maintain Equal Weight Equal Weight
2018-12-07 Deutsche Bank Maintain Buy Buy
2018-11-28 UBS Maintain Neutral Neutral
2018-11-13 Citigroup Maintain Buy Buy
2018-11-08 Keybanc Maintain Overweight Overweight
2018-11-08 KeyBanc Maintain Overweight Overweight
2018-10-16 Barclays Maintain Equal Weight Equal Weight
2018-10-04 Morgan Stanley Maintain Equal Weight Equal Weight
2018-08-08 Citigroup Maintain Buy Buy
2018-06-21 JP Morgan Upgrade Neutral Overweight
2018-04-10 Citigroup Upgrade Neutral Buy
2018-03-06 BMO Capital Maintain Market Perform Perform
2018-02-07 Morgan Stanley Maintain Equal Weight Equal Weight
2018-01-05 KeyBanc Maintain Overweight Overweight
2018-01-03 Evercore ISI Group Maintain Outperform Outperform
2017-11-03 Morgan Stanley Maintain Equal Weight Equal Weight
2017-10-24 Wells Fargo Maintain Outperform Outperform
2017-09-22 Wells Fargo Maintain Outperform Outperform
2017-08-10 Barclays Maintain Equal Weight Equal Weight
2017-06-30 Raymond James Upgrade Outperform Strong Buy
2017-04-24 Evercore ISI Group Upgrade In Line Outperform
2017-01-05 Raymond James Downgrade Strong Buy Outperform
2017-01-03 JP Morgan Downgrade Overweight Neutral
2016-09-23 Citigroup Downgrade Neutral Sell
2016-08-05 UBS Maintain Buy Buy
2016-07-28 Jefferies Maintain Buy Buy
2016-02-11 Deutsche Bank Upgrade Hold Buy
2016-02-04 Citigroup Maintain Neutral Neutral
2016-01-06 Evercore ISI Group Downgrade Buy Hold
2016-01-04 Morgan Stanley Downgrade Overweight Equal Weight
2015-11-12 Citigroup Maintain Neutral Neutral
2015-08-10 Deutsche Bank Maintain Hold Hold
2015-08-07 JP Morgan Maintain Overweight Overweight
2015-06-29 UBS Maintain Buy Buy
2015-03-10 UBS Maintain Neutral Neutral
2015-03-04 JP Morgan Maintain Overweight Overweight
2015-02-06 Deutsche Bank Maintain Hold Hold
2015-01-05 Raymond James Upgrade Market Perform Strong Buy
2014-11-26 JP Morgan Upgrade Neutral Overweight
2014-11-26 Deutsche Bank Maintain Hold Hold
2014-11-05 B of A Securities Maintain Neutral Neutral
2014-11-05 Bank of America Maintain Neutral Neutral
2014-10-14 B of A Securities Maintain Neutral Neutral
2014-10-14 Bank of America Maintain Neutral Neutral
2014-10-07 Argus Maintain Buy Buy
2014-10-07 Stifel Upgrade Hold Buy
2014-10-07 Stifel Nicolaus Upgrade Hold Buy
2014-10-07 Canaccord Genuity Maintain Hold Hold
2014-10-06 Argus Research Maintain Buy Buy
2014-10-06 JP Morgan Upgrade Underweight Neutral
2014-08-01 JP Morgan Maintain Underweight Underweight
2014-08-01 Barclays Maintain Underweight Underweight
2014-06-30 Barclays Maintain Underweight Underweight
2014-02-05 Raymond James Upgrade Underperform Market Perform
2014-01-07 Bank of America Upgrade Underperform Neutral
2014-01-07 B of A Securities Upgrade Underperform Neutral
2013-11-06 Jefferies Maintain Buy Buy
2013-09-18 Piper Sandler Upgrade Neutral Overweight
2013-09-18 PiperJaffray Upgrade Neutral Overweight
2013-08-02 Deutsche Bank Maintain Hold Hold
2013-06-25 ISI Group Maintain Buy Buy
2013-06-24 ISI Group Maintain Buy Buy
2013-05-10 Macquarie Upgrade Neutral Outperform
2013-04-12 Deutsche Bank Maintain Hold Hold
2013-03-28 Jefferies Maintain Buy Buy
2013-01-22 Mizuho Downgrade Buy Neutral
2013-01-04 Deutsche Bank Maintain Hold Hold
2013-01-03 Morgan Stanley Upgrade Underweight Equal Weight
2012-11-20 Stifel Nicolaus Maintain Hold Hold
2012-11-07 Canaccord Genuity Maintain Hold Hold
2012-10-16 Citigroup Maintain Neutral Neutral
2012-09-24 Barclays Downgrade Equal Weight Underweight
2012-08-03 Barclays Maintain Equal Weight Equal Weight
2012-08-03 Leerink Swann Downgrade Outperform Market Perform
2012-08-03 Deutsche Bank Maintain Hold Hold
2012-08-03 CLSA Downgrade Outperform Underperform
2012-08-02 Canaccord Genuity Maintain Hold Hold
2012-08-01 JP Morgan Downgrade Neutral Underweight
2012-07-23 Citigroup Maintain Neutral Neutral
2012-05-02 Deutsche Bank Maintain Hold Hold
2012-02-08 Citigroup Maintain Neutral Neutral